Димиа

Quick links to important sections

Димиа

Selected form

Treatment option: Birth Control

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Димиа

What is Димиа? (The Overview)

Property Description
Active ingredient Drospirenone and Ethinyl Estradiol
Form Oral tablet (film-coated)
Pharmacological class Progestin and Estrogen combination
Common use Prevention of pregnancy
Origin Synthetic steroid hormones

What Type of Medicine is Димиа? (Definition and Classification)

Димиа is classified as a Combined Oral Contraceptive (COC), commonly referred to as a birth control pill, which is used to prevent pregnancy. It belongs to the high-level pharmacological class of Progestin and Estrogen combinations. COCs are a highly effective and widely used method of family planning. This means the medication is globally recognized as a reliable way to manage reproductive health.

As an oral contraceptive, Димиа is taken by mouth daily in the form of a small film-coated oral tablet. This medication is clinically recognized for providing effective, reversible contraception, which is the standard, typical use scenario for this drug.


What are the Active Ingredients in Димиа? (Composition and Origin)

The active ingredients in Димиа are the synthetic hormones Drospirenone (a progestin) and Ethinyl Estradiol (an estrogen). Димиа is designated as a combination pill because it contains both hormone types, which are taken in active sequences followed by a short period of inert (placebo) tablets.

These active agents are synthetic steroid hormones, chemically manufactured to mimic the action of natural hormones. Drospirenone is considered unique among progestins because it possesses anti-mineralocorticoid activity. This specific property of Drospirenone may help mitigate symptoms like fluid retention, which can sometimes be a concern with other combined hormonal contraceptive formulations.


What is the General Benefit of Taking this Specific Pill? (High-Level Purpose)

The primary general benefit of Димиа is that it provides a reliable and predictable method of contraception when used consistently. This high efficacy is structurally supported by its dual hormonal action. In addition to its contraceptive purpose, the use of Combined Oral Contraceptives like Димиа leads to more regular and predictable menstrual cycles. This predictable cycle management is a key general benefit for patients choosing this systemic hormonal method of birth control.

Regulatory References

  1. NIH StatPearls: Oral Contraceptive Pills
  2. WHO: Contraception

What side effects are possible with Димиа?

Possible Side Effects and Safety Information

Димиа (Drospirenone/Ethinyl Estradiol) is a combination hormonal product and its use is associated with a risk of serious cardiovascular events, principally venous and arterial thromboembolic events (VTE and ATE). These include deep vein thrombosis, pulmonary embolism, stroke, and myocardial infarction. The risk of these events is highest during the first year of use and upon restarting the medication after a break of four weeks or more. Smoking and being over 35 years of age significantly increase the risk of serious cardiovascular events, and the medication is officially contraindicated in this population.

Commonly Reported Adverse Reactions:

Frequency Classification Examples of Reactions
Very Common (ge 10%) Headache, Breast pain/discomfort, Menstrual disorders
Common (1% to 10%) Nausea/vomiting, Mood changes, Decrease in libido, Acne, Weight gain

Serious Safety Considerations:

  • Thromboembolic Risk: The primary serious risk involves blood clots. The product must be discontinued prior to major surgery or during prolonged immobilization.
  • Hyperkalemia: Due to drospirenone's anti-mineralocorticoid activity, there is a risk of high potassium levels (hyperkalemia), especially in women with renal or hepatic impairment or those taking specific concomitant potassium-elevating drugs. The medication is contraindicated in patients predisposed to hyperkalemia, and monitoring may be required.
  • Neoplasms and Liver Disease: Use is linked to a small potential increase in the risk of certain cancers, including breast and cervical cancer, and to rare occurrences of benign (adenoma) and malignant liver tumors.
  • Contraindications: Use is restricted and contraindicated in women with a history of VTE/ATE, uncontrolled hypertension, diabetes with vascular disease, severe migraines with aura, known or suspected breast cancer, and active liver disease or impairment.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for a combined oral contraceptive containing Drospirenone and Ethinyl Estradiol (Димиа) defines the manifestations and required emergency response following acute ingestion of a large dose.

Documented Overdose Manifestations

The most commonly reported clinical signs and symptoms of overdose, according to regulatory documents, are nausea, vomiting, and withdrawal bleeding (or vaginal bleeding) in females.

Severity and Emergency Action

Official labeling records that no serious ill effects have been reported following the acute ingestion of large doses by adults or young children. Despite this non-severe risk profile, the regulator-mandated instruction is to seek immediate medical attention for a suspected overdose. The required emergency response includes contacting a Poison Control Center for guidance.

Management and Antidote Status

Management procedures, as officially described, are limited to symptomatic and supportive treatment. Furthermore, the regulatory documents confirm that no specific antidote is known to exist for overdose with this combination of active ingredients. Any necessary observation or monitoring is determined by the attending medical professional based on the severity of the symptoms presented.

Therapeutic Uses of Димиа

What Димиа Treats: Main Uses and Benefits


The primary use of Димиа (Drospirenone and Ethinyl Estradiol) is to provide support for preventing pregnancy, and it is also relevant for managing two specific, hormonally-influenced conditions in women who generally choose to use an oral contraceptive. The medication is used by females of reproductive potential for the prevention of pregnancy, and is relevant for key therapeutic uses, including: providing relief from Premenstrual Dysphoric Disorder (PMDD) symptoms, and assisting with the management of moderate acne vulgaris.

This medication offers symptomatic support in clinical scenarios where symptoms are linked to hormonal fluctuations. The use of this medication helps patients cope more steadily with symptom fluctuations and supports general well-being during symptomatic phases.

Contraception and Cycle Predictability

The most common use is to provide support for preventing pregnancy, assisting with maintaining functional stability related to reproductive health. A secondary benefit is that it supports the establishment of regular menstrual cycles, which contributes to improved comfort during periods of symptomatic change and supports the stability of their monthly routine.

Therapeutic Support for Other Conditions

Димиа is commonly used for managing the symptom burden associated with PMDD, a condition characterized by periods of heightened symptoms. This offers symptomatic support for intense cyclical mood symptoms and associated physical discomforts. Additionally, it is applied in addressing a specific therapeutic need for relief from moderate acne vulgaris, helping to ease the distressing manifestations of the skin condition.

Quick Fact: Relief for Fluid Retention The specific composition of this pill is commonly used to help with cyclical symptoms related to systemic imbalance, such as fluid retention, offering symptomatic relief when symptoms become more noticeable.

Eligibility and Restrictions for Use

Who can and cannot use Димиа? (Drospirenone and Ethinyl Estradiol)

The eligibility criteria for Dimia are strictly defined by regulatory authorities based on population-specific risk profiles and established safety standards.

Populations for whom use is allowed: The medicine is officially approved for use in women of reproductive potential for the prevention of pregnancy. For the management of moderate acne, use is established only in females who have reached menarche (first menstrual period).

Absolute Contraindications (Must Not Use): Use is strictly prohibited for females with a high risk of blood clots, including those over age 35 who smoke, and individuals with a history of deep vein thrombosis, pulmonary embolism, or stroke. The medicine is also formally contraindicated in the presence of uncontrolled high blood pressure, kidney impairment, adrenal insufficiency, liver tumors or liver disease, current or history of breast cancer, and known or suspected pregnancy.

Age and Conditional Restrictions: Dimia is not indicated for the geriatric population and should not be used before menarche. Use is generally not recommended while breastfeeding. It must be discontinued at least four weeks prior to and two weeks after any major surgery or period of prolonged immobilization.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The interaction profile for Димиа is defined by officially documented pharmacokinetic modulation and a specific pharmacodynamic risk. Regulatory documents state that certain drug combinations are strictly prohibited due to potential severe outcomes.

Interaction Classification Interacting Medicines/Classes (Examples)
Formal Contraindication Hepatitis C drug combinations (ombitasvir, paritaprevir/ritonavir, with or without dasabuvir), Oral Tranexamic Acid, Fezolinetant.

Exposure and Efficacy Alterations

The official label describes pharmacokinetic interactions involving the CYP3A4 enzyme system. Enzyme-inducing substances may decrease the concentration of the contraceptive hormones, officially diminishing the effectiveness of the pill. Conversely, co-administration with strong CYP3A4 inhibitors (e.g., Ketoconazole) is documented to increase the exposure of Drospirenone by approximately 2.7-fold and Ethinyl Estradiol by 1.4-fold.

Hyperkalemia Risk and Procedural Constraints

Due to the anti-mineralocorticoid activity of Drospirenone, a pharmacodynamic interaction exists with medications that increase serum potassium. These include drug classes such as ACE inhibitors, Angiotensin-II receptor antagonists, NSAIDs (chronic use), and Potassium-sparing diuretics. For patients on long-term treatment with these medications, regulatory guidance requires checking serum potassium concentration during the first treatment cycle. The drug is contraindicated in patients with renal impairment, hepatic impairment, or adrenal insufficiency.

Mechanism of Action

How Димиа Works: The Mechanism of Action

Primary Molecular Target and Receptor Modulation

Димиа exerts its primary action by engaging defined receptor or enzyme systems, which establishes the initial mechanistic focus. This targeted binding event modifies activity—either by initiating or blocking a specific signal—thereby influencing the commencement of the relevant biological cascade at the cellular level.

Cascade Control and Pathway Dampening

The molecule operates within well-characterized molecular cascades to alter signaling dynamics in defined pathways. It is involved in the modulation of signaling associated with overactive or dysregulated physiological states. This mechanism facilitates the reduction or dampening of excessive signaling, which contributes to a change in activity within the affected system.

Adjusting Central and Peripheral Signaling

Димиа modulates activity in distinct biological systems, including, but not limited to, those governing nerve transmission, inflammatory signaling, or vascular tone. This action supports the alteration of signaling across key regulatory systems, leading to system-level changes in physiological function.

Dosage and Administration Information

How to Use Димиа

The use of this medicine, a combined oral contraceptive containing Drospirenone (3 mg) and Ethinyl Estradiol (0.02 mg), is governed by a strict, cyclic administration schedule. The approved route of administration is oral (by mouth) as a film-coated tablet.


Administration Pattern and Schedule

The standard dosing regimen requires the patient to take one tablet daily on a continuous 28-day schedule. This cycle is fundamentally structured into 24 active hormone tablets followed by four inert, or placebo, tablets.

Crucially, the tablet must be taken at the same time every day to maintain consistent systemic concentrations of the active hormones. The timing of administration is flexible concerning meals; the tablet may be taken with or without food. The entire 28-day course of tablets must be consumed precisely in the order directed on the blister pack, and a new pack is started immediately after the last tablet of the previous pack is finished.


Procedural Conditions

Procedural Requirement Official Instruction
Cycle Start Requirement Use a non-hormonal, back-up contraceptive method during the first seven consecutive days of the initial cycle.
Dose Sequencing Must be followed exactly: 24 active tablets followed by 4 inert tablets.
Missed Dose Specific instructions are provided for handling missed active tablets (e.g., take the missed tablet as soon as possible) to prevent deviation from the intended use pattern.
Age Group Rule Indicated for women at least 14 years of age who have achieved menarche (for the acne indication).

These instructions define the required daily and cyclic pattern for the product, structuring its use to comply with established guidelines.

Recent Clinical Evidence

Dimia: Recent Clinical Evidence

Overview of Approved Uses and Study Focus

Dimia is a brand formulation containing 3 mg drospirenone and 20 mu g ethinyl estradiol (a 24/4 regimen). Clinical research on this combination has historically concentrated on preventing pregnancy, as well as studying potential non-contraceptive benefits in women who choose to use an oral contraceptive.

Key areas of investigation, supported by various trials, include the management of symptoms associated with severe forms of premenstrual syndrome (PMS), specifically Premenstrual Dysphoric Disorder (PMDD), and the treatment of moderate acne vulgaris.


Efficacy and Outcome Measures

  • PMDD: Clinical trials evaluating the drospirenone/ethinyl estradiol combination have shown that participants reported a significant decrease in the intensity of PMDD and severe PMS manifestations, often resulting in an improvement in quality of life measures. This formulation is the only hormonally based contraceptive regimen with clinical trials demonstrating efficacy specifically for PMDD.
  • Acne Vulgaris: Studies demonstrated that the combination was effective in treating moderate acne in women. The presence of the progestin drospirenone, which has antiandrogenic properties, is considered a contributing factor to the observed effects on acne symptoms.
  • Dysmenorrhea: Systematic reviews and meta-analyses suggest that the 20 mu g ethinyl estradiol/drospirenone 3 mg combination may improve symptoms of dysmenorrhea (painful periods) and decrease related pain symptoms.

Safety and Tolerability Profile

Studies have evaluated the overall safety profile, with frequent reported adverse events including headache/migraine, breast tenderness, nausea, and menstrual irregularities. A notable aspect of the research is the focus on the risk of venous thromboembolism (VTE). Studies have suggested that drospirenone-containing contraceptives may be associated with a higher risk of VTE than those containing some other progestins, such as levonorgestrel. Prescribers are advised to consider this VTE risk, particularly in new users, against a woman's individual risk factors.

Key Studies & References

  1. Drospirenone/ethinyl estradiol (24/4) and its application in the management of premenstrual dysphoric disorder (PMDD) and moderate acne vulgaris
  2. Efficacy and safety of combined ethinyl estradiol/drospirenone oral contraceptives in the treatment of acne - Systematic Review

Frequently Asked Questions (FAQ)

Common questions about Димиа (FAQ)


Q: How long does it take for this birth control to become fully effective?

According to official product information, if the first pill is started later than the first day of a woman's menstrual cycle, a non-hormonal, back-up method of contraception is advised in the product information. This back-up method is noted for the first 7 consecutive days of taking the active hormone pills.


Q: What is the purpose of the 4 inactive (placebo) tablets in the 24/4 regimen?

The official documentation explains that the pill regimen consists of 24 active hormone pills followed by 4 inactive, or placebo, pills. These inactive tablets are included in the 28-day schedule primarily to help maintain the daily habit of taking a pill. The time when a person takes the inactive pills is the hormone-free interval, which typically results in a withdrawal bleed.


Q: Is there a specific age or smoking status cutoff that would prevent me from taking this, even if I'm otherwise healthy?

Yes, regulatory documents include warnings regarding age and smoking status. The medication is formally contraindicated (must not be used) in females who are over 35 years of age and smoke due to a significantly increased risk of serious cardiovascular events, such as blood clots or stroke.


Q: If I experience common side effects like spotting or nausea, how long should I wait before they resolve?

Official information indicates that irregular bleeding, often called spotting or breakthrough bleeding, is a common occurrence, particularly during the first few months of use. This type of bleeding usually resolves as the body adjusts to the medication. However, if the bleeding persists beyond a few cycles or causes concern, consultation with a healthcare provider is noted in official guidance.


Q: Does this birth control interact with any common over-the-counter medications, like antibiotics or herbal supplements?

Yes, official labeling describes potential interactions that can affect the pill's efficacy. Certain medicines, including some antibiotics (like rifampin), anticonvulsants, and the herbal supplement St. John's Wort, may reduce how well the pill works. For patients using interacting medications, a non-hormonal back-up method of contraception may be noted as necessary in the product information.


Q: When can I start taking this after giving birth if I am not breastfeeding?

For women who are not breastfeeding, regulatory guidance advises against starting the medication too soon after delivery. It is generally recommended that therapy begins no earlier than 4 weeks after delivery. This instruction is based on managing the increased risk of blood clots that occurs in the postpartum period.


Q: What are the specific symptoms or warning signs that mean I must contact a healthcare professional immediately?

The official patient information notes that immediate medical attention is necessary if symptoms associated with a blood clot occur. These signs may include severe leg pain, unexplained shortness of breath, sudden severe headache or migraine with aura, or sudden disturbances in vision. These symptoms represent serious safety concerns documented in regulatory warnings.


Q: Will this pill make my menstrual periods lighter or shorter?

Studies and official information indicate that the combined use of these hormones works to stabilize the endometrial lining. While the medication is associated with menstrual irregularities, clinical data suggests that it may lead to decreased menstrual flow or lighter periods for some users.


Q: Is this considered a 'low-dose' oral contraceptive?

Yes. The official dosage form indicates that the product contains 0.02 mg (20 micrograms) of ethinyl estradiol. This amount is generally considered a low dose of the estrogen component in combined oral contraceptive pills.


Q: Should I avoid eating or drinking grapefruit while taking this medication?

Regulatory information indicates that grapefruit or grapefruit juice may increase the blood level of one of the active ingredients, drospirenone. For this reason, official guidance may note limiting or completely avoiding consumption of grapefruit products.


Q: Does this pill cause abnormal liver function tests in healthy users?

The medication is metabolized in the liver and is contraindicated for use in individuals with known liver disease or impairment. The estrogen component may be associated with changes in liver enzyme levels, and there is a noted risk of liver enzyme elevations when used with certain Hepatitis C drug regimens.


Q: I am lactose intolerant. Does this product contain lactose or sugar?

Yes, official regulatory documents list the inactive ingredients of the tablets. These documents confirm that the tablets contain lactose monohydrate as an inactive component (excipient).

How should Димиа be stored and disposed of?

The storage and disposal of Dimia (Drospirenone and Ethinyl Estradiol) must align strictly with official regulatory requirements to ensure product integrity.

Official Storage Conditions

Requirement Specifics from Regulatory Labeling
Temperature Range Store at controlled room temperature, 20 C to 25 C (68 F to 77 F). Excursions between 15 C and 30 C are permitted.
Environmental Protection Keep in the original container and protect the tablets from light and moisture.
Child Safety The medicine must be stored out of the sight and reach of children.

Labeled Disposal Instructions

Unused or expired Dimia must be disposed of properly to prevent environmental contamination. The official instructions prohibit disposal via wastewater or household waste. Instead, the unused product must be returned to a pharmacist or an approved local waste disposal company.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Димиа found in:

A-Z Index: